YD Bio Limited Warrants
YDESW - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.22M
Close$
$-0.10
115.3% downside
Current Fair Value
115.3% downsideOvervalued by 115.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $2.22 Million |
|---|---|
| Enterprise Value | $-242,245.00 |
| Earnings per Share | $-0.12 |
| Beta | -0.13 |
| Outstanding Shares | 3,409,483 |
Return
| Return on Equity | -66.49% |
|---|---|
| Return on Assets | -29.57% |
| Return on Invested Capital | -33.22% |
Valuation & Multiples
| P/E Ratio | -56.08 |
|---|---|
| PEG | 49.65 |
| Price to Sales | - |
| Price to Book Ratio | 0.65 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -116.57 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About YD Bio Limited Ordinary Shares
4 employees
CEO: Ethan Shen
Breeze Holdings Acquisition Corp. operates as a clinical-stage biopharmaceutical company focuses on cancer prevention medical diagnostics and the development of exosome-based therapeutics with the potential to transform the treatment of ...